Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Cephalon
Woman Max 99 years
Cephalon France
Update Il y a 4 ans
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naïve Patients With HER2-Positive Breast Cancer
To compare the efficacy of up to 8 cycles (24 weeks) of MYOCET plus cyclophosphamide and trastuzumab for 4 cycles followed by docetaxel plus trastuzumab for 4 cycles (MCH→TH) with free doxorubicin plu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man
Between 18 years and 70 years
Cephalon
Update Il y a 4 ans
CEPHALON C19562/2037/BC/EU : Essai de phase 2 randomisé évaluant l’efficacité et la tolérance d’un traitement avec de la doxorubicine (Myocet®) et de la cyclophosphamide associé ou non à du trastuzumab, en traitement néo-adjuvant, chez des patientes ayant un cancer du sein HER2+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Prospective, open-label, randomized study of combination therapy of Myocet® plus cyclophosphamide and trastuzumab versus free doxorubicin plus cyclophosphamide alone, each followed by docetaxel and tr...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Cephalon, Inc
Update Il y a 4 ans
Estudio de extensión abierto del fármaco oral CEP-701 en pacientes con enfermedades malignas hematológicas y no hematológicas que han participado en un estudio clínico del CEP-701
To assess the safety and tolerability of long term administration of CEP 701 in patients with advanced malignancy.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Cephalon, Inc
Update Il y a 4 ans
The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used for 6 months with mood stabilizers in subjects with major depression associated with bipolar I disorder
The primary objective of this study is to evaluate the safety and tolerability of long-term (6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in adults with bipola...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Cephalon
Update Il y a 4 ans
C18770/2043 : Essai de phase 1-2, visant à déterminer la dose maximale tolérée et à évaluer l’efficacité et la tolérance du CEP-19770, chez des patients ayant un myélome multiple en rechute et réfractaire au traitement le plus récent. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai de déterminer la dose le plus adaptée, puis l’efficacité et la tolérance du CEP-18770, chez des patients ayant un myélome multiple en rechute et réfractaire au traitement le pl...
Country
France
organs
Myélomes
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Cephalon, Inc
Update Il y a 4 ans
An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine if armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy for adults who are experiencing a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Cephalon
Update Il y a 4 ans
CEPHALON C9722 : Essai de phase 1 évaluant la tolérance d’un traitement par un inhibiteur de PARP-1 et 2 (CEP-9722) associé ou non au témozolomide, chez des patients ayant une tumeur solide avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) as single-agent therapy and as combination therapy with temozolomide in p...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Cephalon UK Independent Research Programme grant (UK)
Update Il y a 4 ans
A randomised, placebo-controlled, rising dose, crossover study to evaluate the effectiveness of modafinil in the management of fatigue in fibromyalgia
Not provided at time of registration
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Cephalon France
Update Il y a 4 ans
A European Multicenter Open-label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
The primary objective of the study is to compare the percentage of patients reaching an effective fentanyl buccal tablet (FBT) dose with a starting dose of 100 mcg (Group A) to those with a starting d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Cephalon, Inc
Update Il y a 4 ans
A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury
The primary objective of the sudy is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with mild or moderate closed t...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
Next